Ipsen reports positive data from Alzheimer’s trial

Ipsen has published data from a major new clinical trial, which illustrates the potential benefits of its Alzheimer’s disease treatment EGb 761.

The drug was trialled among 2,854 patients during the five-year GuidAge study, which represents the longest and largest European Alzheimer’s disease study yet conducted.

It was found that a statistically significant number of patients using Ipsen’s drug were able to experience benefits for at least four years compared to those on placebo, while the long-term safety profile of the treatment was also confirmed.

Dr Patrick Merat, senior vice-president of drug development and chief medical officer at Ipsen, expressed satisfaction with the groundbreaking trial and stated that the information collated represents a “valuable source of knowledge”.

He added: “It is Ipsen’s intention to assess all the potential strategies so as to carry these findings further.”

Last week, the company was granted a positive regulatory recommendation for OBI-1, its new treatment for haemophilia, to be granted orphan drug status in Europe.